ISPOR POLAND CHAPTER Polish Society of Pharmacoeconomics (PTFe )

Slides:



Advertisements
Similar presentations
Building an EU consensus for minimum quality standards in the prevention, treatment and harm reduction of drugs Quality Standards - Policy Perspectives.
Advertisements

HTA Consulting 11 years experience Our proposal for European Countries
Engaging Patients and Other Stakeholders in Clinical Research
Thailand National Focal Point for IFCS Chemical Safety Section Food and Drug Administration Ministry of Public Health July 2003.
PHARMACOECONOMICS THE ROLE OF PHARMACOECONOMICS FROM THE PHARMACOECONOMICS ON THE INTERNET ®SERIES © Paul C Langley, 2004 Maimon Research LLC.
Health & Consumer Protection Directorate General The EU Health Strategy and the new Health and Consumer Protection Programme Bernard Merkel Paula.
The Standards of Practice for a Tobacco Treatment Specialist (TTS) Gaylene Mooney, M.Ed., RRT-NPS, CTTS Program Director, Respiratory Therapy San Joaquin.
Asia Consortium Regional chapter in Asia ISPOR-INDIA Chapter Jawahar Bapna PhD, MD, MBBS Adjunct Professor, Pharmaceutical Management Institute of Health.
Update on a recently launched European R&D endeavour: The Innovative Medicines Initiative (IMI) FERS meeting Brussels, 7 th April 2008.
International Society for Pharmacoeconomics and Outcomes Research updated June 2010
The Wise List experience in Stockholm and resulting Drug Utilization studies Björn Wettermark M.Sc.Pharm, Associate professor Karolinska Institutet and.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Focusing on the key challenges Decision-making & drug development Peter Hertzman Paul Miller.
MOSCOW PHARMACEUTICAL SOCIETY MOSCOW PHARMACEUTICAL SOCIETY REGIONAL NONCOMMERCIAL ORGANIZATION MPhS ANNUAL REPORT 2014.
ISPOR CHAPTERS: CENTRAL & EASTERN EUROPE Czech Chapter Poland Chapter Russia Chapter Serbia Chapter Slovakia Chapter Turkish SCP Chapter + Israel Chapter.
Clinical Pharmacy Basma Y. Kentab MSc..
Rare Diseases Foundation Céline Hubert Pr Nicolas Lévy
PHARMACOECONOMICS and RATIONAL DRUG USE DRAFT PROGRAM FOR 1 st ISPOR INTERNATIONAL SUMMER SCHOOL ISPOR SCP (TURKEY) ANTALYA, APRIL 17-21, 2008 PHARMACOECONOMICS.
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
The involvement of patients in Health Technology Assessment Andrzej Rys Director Health and Consumers Directorate-General Brussels 18 May 2010.
Conference: Generic Drugs in Turkey and the EU THE PORTUGUESE MODEL FOR STIMULATING GENERIC COMPETITION IN THE EU June 2, 2005, Ankara, Turkey Rui Santos.
CZECH CHAMBER OF COMMERCE – Bench mark in Business Aid for Trade – Introduction Presentation by Jiří Hansl, M.A. Serbia, October 2012.
Presentation by Lia van Ginneken – EMP Secretary & João Salazar – EMP Chairman 21st February 2009.
The competition between innovative and generic pharmaceutical companies intensified in the last decades. The models created by innovative pharmaceutical.
The Regional Platform for Access and Innovation for Health Analía Porrás Medicines and Health Technologies (HSS/MT) Health Systems based on Primary Health.
Clinical Pharmacy Part 2
HTA and Health Care Decisions in Slovakia. PharmDr. Martin Višňanský, MBA, PhD. President - ISPOR Local Chapter, Slovakia Slovak Agency for Health Technology.
Workshop The science and methodologies behind HTA, diversity and commonality across the EU Achieving more patient centred HTA in different countries.
ISPOR Polish Chapter Accomplishments and plans for 2007/2008.
SCIENTIFIC AND RESEARCH ACTIVITIES IN THE FIELDS OF CRISIS MANAGEMENT AND CIVIL PROTECTION Tomasz Plasota, Bartłomiej Połeć 1 Scientific and Research Centre.
HTA cooperation in the EU EPF workshop Jérôme Boehm 18 May 2010.
Supporting tough decisions: linking Health technology assessment (HTA) and national priority setting in Norway Ånen Ringard 1, Berit Mørland 1,2 1 Secretariat.
Tony, Yen-Huei Tarn, M.S., Ph.D. President, TaSPOR Introduction of Taiwan Society for Pharmacoeconomics and Outcomes Research (TaSPOR) ISPOR 2ND ASIA-PACIFIC.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
1 10 th Annual European Scientific and Regulatory Affairs Conference New Pharmaceutical legislation: One year experience… 21 November 2006 Bernard Lemoine.
Supporting Informed Formulary Decision Making: CADTH’s Common Drug Review Denis Bélanger, Director, CADTH New Brunswick Stroke Summit November 27, 2010,
Graduate studies - Master of Pharmacy (MPharm) 1 st and 2 nd cycle integrated, 5 yrs, 10 semesters, 300 ECTS-credits 1 Integrated master's degrees qualifications.
Drug Policy Experience of Visegrad Group countries, Warszava Oct 29-30, 2007 System of counting of reimbursement costs in the Czech Republic Tomas Sechser.
A Strategic Research Agenda for Europe in the field of illicit drugs Priorities for socio-economic and humanities research HDG Brussels - December 10,
A presentation of The Association of the Pharmaceutical Industry in Norway (LMI)
Use of Pharmacoeconomics & Outcomes Research Information in Health Care Decisions – SURVEY Results Peter K Wong, PhD, MS, MBA, RPh Steve Marx, PharmD,
DETERMINE Working document # 4 'Economic arguments for addressing social determinants of health inequalities' December 2009 Owen Metcalfe & Teresa Lavin.
1 Need for co-operation of Visegrad - group countries and ways of its organization Warsaw, Oct , 2007.
EU COST Action IS 1402 Berlin, WG1 group/subgroup meetings.
Peter Scherer Head, Health Division 7 th Meeting of Health Accounts Experts and Correspondents for Health Expenditure Data Paris, September 2005.
Workshop 18 th May 2010, Brussels Applying the Value+ model on patient involvement in HTA processes.
Alun JONES EU Network Manager European Agency for Safety and Health at Work 6 th Framework Programme on Research.
Progress Report of Taiwan Society for Pharmacoeconomics and Outcomes Research (TaSPOR) ISPOR 15th Annual International Meeting Hilton Atlanta, Atlanta.
By: Nicole Giardina. History of AMA AMA was founded on May 7, 1847 by Nathan Smith Davis. The meeting to create the AMA was held in the Academy of Natural.
Gaps in Substance Use Treatment Presented by: Rhonda G. Patrick, LCSW, MPA Amy C. Traylor, MSW, Ph.D.
EHFG 7 October 2005 – Patient Safety & Research UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005 Kevin McCarthy, European.
2010 ISPOR Board of Directors Open Meeting ISPOR Shanghai Chapter Interim President Wen Chen, Ph.D., Professor.
National Information Day Greece 23 July 2015 Funding priorities under the work plan 2015.
Health Technology Assessment Methodology, an EUnetHTA View Basics for the Assessment in EU Countries PharmDr. Martin Visnansky, MBA, PhD., MSc. (HTA) HTA.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
Patient Engagement throughout the Biopharmaceutical Lifecycle: Tips for Effective Patient Advocate/Industry Collaboration to Improve Patient Access and.
 The Work of Civil Society in the Field of HIV Prevention Brussels, 23 February 2011 The Work of European AIDS Treatment Group (EATG) 1.
A capacity building programme for patient representatives
MEP Interest Group on Brain, Mind and Pain
Tomasz Plasota, Bartłomiej Połeć
Community Pharmacy: Sharing Our Vision
Cooperation for Better Regulation
Antimicrobial Resistance: Plans for Korea and Beyond
KEY STAKEHOLDERS PERCEPTIONS OF HEOR USAGE IN LEBANON
The International Consortium for Personalised Medicine
Kaisa Immonen EPF Director of Policy
کتابهای خریداری شده فن آوری اطلاعات سلامت 1397
Realizing effective health technology assessment for the SA healthcare environment Praneet Valodia The BHF Southern African Conference July’07.
Presentation transcript:

ISPOR POLAND CHAPTER Polish Society of Pharmacoeconomics (PTFe )

International examples Acceptedmultidisciplinary methodology methodology PharmacoeconomicsinPoland Optimizing pharmacotherapy through rational drugs management

Pharmacoeconomics in Poland Regulations Methodology/Standardization Polish terminology Existing resources Educational opportunities

REGULATIONS 1.Act on Health Services Financed from Public Sources a)Necessity of justyfying proposed price b)Evidence on clinical efficiacy, cost- effectiveness and budget impact analysis (for innovative drugs) 2.Act on Prices 3.Regulations concerning Health Technology Assessment Agency a)Economic evaluation including cost analysis b)Influence on financing from public sources 4.Requirements concerning Treatment Programmes financed by the National Health Fund a)Defining cost-endpoint relationship

METHODOLOGY/TERMINOLOGY 1.Polish Guidlines for conducting pharmacoeconomic evaluations (2000) approved by ISPOR Polish Chapter 2.The Polish Dictionary of Pharmacoeconomics 1st and 2nd editions 3.Textbooks and manuals

Limit prices for reimbursed drugs The same active substance, different market price. Generic limit price Therapeutic limit price Different active substances, the same effect, different market price. REIMBURSEMENT SYSTEM Fixed charge 70%50% Basic and supplementary list

ISPOR POLAND CHAPTER in Organizing the 3rd Scientific Conference of the Polish Society of Pharmacoeconomics: („Reimbursement systems in EU countries; discussion about activities of the Society members in working groups of ISPOR Organizing the 3rd Scientific Conference of the Polish Society of Pharmacoeconomics: („Reimbursement systems in EU countries; discussion about activities of the Society members in working groups of ISPOR 1. Working on the 4th Scientific Conference of the Polish Society of Pharmacoeconomics (focused on : pharmacoeconomics and economic evaluation of heath care programs; prof. Paul Kind as a main speaker: “Patient reported outcomes and quality of life”; inviting Czech and Russian ISPOR Chapters Presidents 2. Creating Student Section within the Polish Society of Pharmacoeconomics with 25 members in order to promote interest and awareness about pharmacoeconomics, health outcome research to various disciplines across members of health-related organizations and universities in Poland 3. Educational support of Student Section by PTFE – lectures –„Pharmacoeconomics in Polish perspective” –„Health and economics” prof. Tomasz Hermanowski

ISPOR POLAND CHAPTER in Cooperation with medical societies in educational area – lectures on pharmacoeconomics for relevant scientific and medical societies 2. Discussion with representatives of the Ministry of Health about principles of pricing and reimbursement system in Poland in relation to pharmacoeconomics 3. Discussion with the Association of Pharmaceutical Industry in Poland on the Code of Marketing Ethics. Stating an objection against the use of pharmacoeconomic studies as a marketing tool. Stating an objection against the use of pharmacoeconomic studies as a marketing tool. 4. Representing the Polish Society of Pharmacoeconomics on the following conferences: the 7th Congress of European Association for Clinical Pharmacology and Thearpautics” the 7th Congress of European Association for Clinical Pharmacology and Thearpautics” Lectures about the role of pharmacoeconomics in drug policy, Lectures about the role of pharmacoeconomics in drug policy, Conference of Quality Management Center, Cracow, Conference of Quality Management Center, Cracow, Workshop for hospitals’ directors and pharmacists: ’’Pharmacoeconomics in atreatment process”, Oct Workshop for hospitals’ directors and pharmacists: ’’Pharmacoeconomics in atreatment process”, Oct participation in experts panel „How clinical trials for new drugs should be financing?”, Oct participation in experts panel „How clinical trials for new drugs should be financing?”, Oct. 2006